Registration Dossier

Data platform availability banner - registered substances factsheets

Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.

The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.

Diss Factsheets

Administrative data

Description of key information

Key value for chemical safety assessment

Additional information

Justification for classification or non-classification

Repeated oral gavage administration of NBI-98854 in rats was tolerated up to 15 mg/kg/day. The effects of dopamine depletion included sedation, lethargy, tremors at rest, rigidity, unsteady gait or posture, bradykinesia, respiratory depression, and hyperprolactinemia. Repeated oral doses of NBI-98854 administered over a period of 14 days (up to 35 mg/kg/day to dogs were tolerated up to 15 mg/kg/day. Clinical observations associated with all NBI-98854 doses included decreased activity, lethargy, and recumbency. Ataxia, trembling, unsteady head, and excessive salivation were observed consistently at >15 mg/kg/day. Convulsions and emesis were noted at the highest dose of NBI-98854 tested in dogs (35 mg/kg/day).